康希诺生物(06185.HK)拟将H股所得款项部分转为在研疫苗开发及收购相关资产
康希诺生物(06185.HK)公布,截至今年6月30日,公司首次公开发售所得款项中约6.83亿元人民币(下同)仍然尚未使用。公司决议建议更改仍然尚未使用的首次公开发售所得款项的用途。
公司建议,原计划用於在研MCV的研发及商业化的4.2亿元未使用所得款项之建议分配,拟转为用於先进技术、在研疫苗及生物制品的合作、许可及引入;在研疫苗的开发;及收购与疫苗及生物制品相关的优质资产。
公司指,於今年8月13日,公司已完成发行A股,并於上交所科创板上市。考虑本次A股发行获得的募集资金净额,连同与Pfizer的市场合作及公司的营运需要,为加强公司的资金使用效率,建议将原本分配作在研MCV商业化的部分尚未使用首次公开发售所得款项重新分配。公司在研MCV的商业化将以自A股发行获得的超募资金拨支。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.